Cachet Pharmaceutical Co Ltd Net Assets
Cachet Pharmaceutical Co Ltd net assets. Based on the latest financial reports, Cachet Pharmaceutical Co Ltd (002462) has net assets worth CN¥5.90 Billion CNY (≈ $864.00 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥11.93 Billion ≈ $1.75 Billion USD) and total liabilities (CN¥6.02 Billion ≈ $881.58 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Cachet Pharmaceutical Co Ltd to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.90 Billion |
| % of Total Assets | 49.5% |
| Annual Growth Rate | 13.76% |
| 5-Year Change | 3.88% |
| 10-Year Change | 100.18% |
| Growth Volatility | 20.81 |
Net Assets of Cachet Pharmaceutical Co Ltd (2007–2025)
Net assets of Cachet Pharmaceutical Co Ltd from 2007 to 2025. This chart illustrates how Cachet Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See 002462 equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Cachet Pharmaceutical Co Ltd (2007–2025)
The table below shows the annual net assets of Cachet Pharmaceutical Co Ltd from 2007 to 2025. For live market cap and overall valuation, see Cachet Pharmaceutical Co Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥5.88 Billion ≈ $859.82 Million |
-3.12% |
| 2024-12-31 | CN¥6.06 Billion ≈ $887.48 Million |
-0.44% |
| 2023-12-31 | CN¥6.09 Billion ≈ $891.38 Million |
+2.87% |
| 2022-12-31 | CN¥5.92 Billion ≈ $866.52 Million |
+4.69% |
| 2021-12-31 | CN¥5.66 Billion ≈ $827.73 Million |
+6.25% |
| 2020-12-31 | CN¥5.32 Billion ≈ $779.07 Million |
+8.15% |
| 2019-12-31 | CN¥4.92 Billion ≈ $720.37 Million |
+31.88% |
| 2018-12-31 | CN¥3.73 Billion ≈ $546.21 Million |
+16.75% |
| 2017-12-31 | CN¥3.20 Billion ≈ $467.85 Million |
+8.92% |
| 2016-12-31 | CN¥2.94 Billion ≈ $429.52 Million |
+33.30% |
| 2015-12-31 | CN¥2.20 Billion ≈ $322.23 Million |
+31.50% |
| 2014-12-31 | CN¥1.67 Billion ≈ $245.05 Million |
+28.48% |
| 2013-12-31 | CN¥1.30 Billion ≈ $190.72 Million |
+15.59% |
| 2012-12-31 | CN¥1.13 Billion ≈ $165.01 Million |
+3.42% |
| 2011-12-31 | CN¥1.09 Billion ≈ $159.55 Million |
+6.41% |
| 2010-12-31 | CN¥1.02 Billion ≈ $149.95 Million |
+81.71% |
| 2009-12-31 | CN¥563.92 Million ≈ $82.52 Million |
+18.71% |
| 2008-12-31 | CN¥475.03 Million ≈ $69.51 Million |
-17.74% |
| 2007-12-31 | CN¥577.44 Million ≈ $84.50 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Cachet Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1163.6% over the analyzed period, indicating profitable operations and earnings retention.
Cachet Pharmaceutical Co Ltd Net Assets Breakdown (December 2025)
Cachet Pharmaceutical Co Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.54 Billion | 58.38% |
| Common Stock | CN¥291.71 Million | 6.70% |
| Other Comprehensive Income | CN¥241.31 Million | 5.55% |
| Other Components | CN¥1.28 Billion | 29.37% |
| Total Equity | CN¥4.35 Billion | 100.00% |
Cachet Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Cachet Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WenYi Trinity Technology Co Ltd
SHG:600520
|
$457.64 Million |
|
Laxmi Organic Industries Limited
NSE:LXCHEM
|
$457.91 Million |
|
Tianjin Tianbao Infrastructure Co Ltd
SHE:000965
|
$457.98 Million |
|
CHC Resources Corp
TW:9930
|
$458.08 Million |
|
Shaanxi Xinghua Chemistry Co Ltd
SHE:002109
|
$457.56 Million |
|
Coca-Cola Europacific Partners PLC
LSE:CCEP
|
$457.55 Million |
|
Guggenheim Active Allocation Fund
NYSE:GUG
|
$457.43 Million |
|
Shenzhen Deren Electronic Co Ltd
SHE:002055
|
$457.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cachet Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,326,637,737 to 4,351,804,983, a change of 25,167,246 (0.6%).
- Net income of 111,378,719 contributed positively to equity growth.
- Dividend payments of 108,868,996 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥111.38 Million | +2.56% |
| Dividends Paid | CN¥108.87 Million | -2.5% |
| Other Changes | CN¥22.66 Million | +0.52% |
| Total Change | CN¥- | 0.58% |
Book Value vs Market Value Analysis
This analysis compares Cachet Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.72x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 3.42x to 0.72x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥3.13 | CN¥10.72 | x |
| 2008-12-31 | CN¥2.59 | CN¥10.72 | x |
| 2009-12-31 | CN¥3.09 | CN¥10.72 | x |
| 2010-12-31 | CN¥5.05 | CN¥10.72 | x |
| 2011-12-31 | CN¥4.49 | CN¥10.72 | x |
| 2012-12-31 | CN¥4.56 | CN¥10.72 | x |
| 2013-12-31 | CN¥4.92 | CN¥10.72 | x |
| 2014-12-31 | CN¥5.36 | CN¥10.72 | x |
| 2015-12-31 | CN¥5.96 | CN¥10.72 | x |
| 2016-12-31 | CN¥7.90 | CN¥10.72 | x |
| 2017-12-31 | CN¥8.79 | CN¥10.72 | x |
| 2018-12-31 | CN¥9.98 | CN¥10.72 | x |
| 2019-12-31 | CN¥13.12 | CN¥10.72 | x |
| 2020-12-31 | CN¥12.46 | CN¥10.72 | x |
| 2021-12-31 | CN¥13.29 | CN¥10.72 | x |
| 2022-12-31 | CN¥14.01 | CN¥10.72 | x |
| 2023-12-31 | CN¥14.58 | CN¥10.72 | x |
| 2024-12-31 | CN¥14.81 | CN¥10.72 | x |
| 2025-12-31 | CN¥14.85 | CN¥10.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cachet Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.57%
- • Asset Turnover: 1.53x
- • Equity Multiplier: 2.93x
- Recent ROE (2.56%) is below the historical average (10.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 32.37% | 27.55% | 0.77x | 1.52x | CN¥126.20 Million |
| 2008 | 8.75% | 4.28% | 1.31x | 1.55x | CN¥-5.92 Million |
| 2009 | 7.55% | 3.74% | 1.24x | 1.63x | CN¥-13.74 Million |
| 2010 | 4.75% | 3.62% | 0.94x | 1.40x | CN¥-53.65 Million |
| 2011 | 6.01% | 3.54% | 1.14x | 1.49x | CN¥-42.21 Million |
| 2012 | 5.96% | 2.55% | 1.33x | 1.75x | CN¥-44.23 Million |
| 2013 | 10.97% | 3.67% | 1.27x | 2.35x | CN¥11.49 Million |
| 2014 | 17.72% | 4.09% | 1.23x | 3.53x | CN¥99.34 Million |
| 2015 | 12.08% | 2.11% | 1.39x | 4.11x | CN¥29.84 Million |
| 2016 | 11.26% | 2.03% | 1.49x | 3.72x | CN¥24.99 Million |
| 2017 | 11.94% | 1.85% | 1.55x | 4.17x | CN¥42.92 Million |
| 2018 | 13.12% | 1.82% | 1.66x | 4.34x | CN¥77.91 Million |
| 2019 | 10.98% | 1.69% | 1.70x | 3.81x | CN¥33.40 Million |
| 2020 | 8.75% | 1.37% | 1.65x | 3.89x | CN¥-45.31 Million |
| 2021 | 9.11% | 1.38% | 1.72x | 3.84x | CN¥-34.78 Million |
| 2022 | 7.28% | 1.13% | 1.58x | 4.06x | CN¥-110.87 Million |
| 2023 | 5.90% | 0.83% | 1.75x | 4.04x | CN¥-173.99 Million |
| 2024 | 3.71% | 0.67% | 1.71x | 3.24x | CN¥-272.00 Million |
| 2025 | 2.56% | 0.57% | 1.53x | 2.93x | CN¥-323.80 Million |
Industry Comparison
This section compares Cachet Pharmaceutical Co Ltd's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $1,648,966,099
- Average return on equity (ROE) among peers: 13.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cachet Pharmaceutical Co Ltd (002462) | CN¥5.90 Billion | 32.37% | 1.02x | $457.59 Million |
| Yunnan Hongxiang Yixintang (002727) | $262.78 Million | 32.29% | 1.61x | $1.14 Billion |
| Luyan Pharma Co Ltd (002788) | $746.00 Million | 15.21% | 3.60x | $533.84 Million |
| Ji Yao Holding Group Co Ltd (300108) | $-366.31 Million | 0.00% | 0.00x | $20.47 Million |
| ShuYu Civilian Pharmacy Corp. Ltd. (301017) | $2.37 Billion | 5.62% | 2.94x | $822.04 Million |
| Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) | $1.85 Billion | 1.44% | 2.34x | $261.19 Million |
| Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) | $947.01 Million | 16.98% | 1.72x | $796.06 Million |
| Shanghai No1 Pharmacy Co Ltd (600833) | $186.74 Million | 13.27% | 2.88x | $312.41 Million |
| Dashenlin Pharm Grp Co Ltd (603233) | $7.93 Billion | 14.70% | 2.04x | $3.38 Billion |
| Laobaixing Pharmacy (603883) | $916.46 Million | 17.54% | 1.38x | $1.66 Billion |
About Cachet Pharmaceutical Co Ltd
Cachet Pharmaceutical Co., Ltd. engages in the wholesale, retail, and logistics of pharmaceutical products in China. The company also offers medical drugs, medical devices, e-commerce products, and warehousing logistics services. It sells its products through online and offline channels. The company was founded in 1997 and is headquartered in Beijing, China.